Get the Stockscreener App
99.65
2.70%
2.62
After Hours:
99.65
Axsome Therapeutics Inc stock is traded at $99.65, with a volume of 481.80K.
It is up +2.70% in the last 24 hours and up +10.88% over the past month.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
See More
Previous Close:
$97.03
Open:
$97.77
24h Volume:
481.80K
Relative Volume:
1.03
Market Cap:
$4.72B
Revenue:
$291.49M
Net Income/Loss:
$-308.55M
P/E Ratio:
-22.00
EPS:
-4.53
Net Cash Flow:
$-168.02M
1W Performance:
+5.34%
1M Performance:
+10.88%
6M Performance:
+32.53%
1Y Performance:
+50.39%
1-Day Range:
$96.50
$100.48
1-Week Range:
$94.24
$100.61
52-Week Range:
$64.11
$105.00
Axsome Therapeutics Inc Stock (AXSM) Company Profile
Name
Axsome Therapeutics Inc
Sector
Industry
Phone
(212) 332-3241
Address
ONE WORLD TRADE CENTER, 22ND FLOOR, NEW YORK
Compare AXSM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AXSM
Axsome Therapeutics Inc
|
99.65 | 4.72B | 291.49M | -308.55M | -168.02M | -4.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Axsome Therapeutics Inc Stock (AXSM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-03-24 | Initiated | Wells Fargo | Overweight |
| Aug-06-24 | Upgrade | BofA Securities | Neutral → Buy |
| Jul-22-24 | Initiated | Needham | Buy |
| Apr-29-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-19-24 | Initiated | Robert W. Baird | Outperform |
| Feb-06-24 | Initiated | UBS | Buy |
| Jan-25-24 | Initiated | RBC Capital Mkts | Outperform |
| Dec-13-23 | Initiated | Citigroup | Buy |
| Aug-08-23 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-05-23 | Initiated | Piper Sandler | Neutral |
| Nov-01-22 | Initiated | Loop Capital | Buy |
| Sep-07-22 | Resumed | Mizuho | Buy |
| Aug-10-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-10-21 | Initiated | Berenberg | Buy |
| Jan-08-21 | Initiated | Jefferies | Buy |
| Dec-16-20 | Initiated | Mizuho | Buy |
| Sep-29-20 | Initiated | BofA Securities | Underperform |
| Sep-10-20 | Initiated | Morgan Stanley | Overweight |
| Apr-28-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-14-20 | Initiated | Cowen | Outperform |
| Dec-30-19 | Reiterated | H.C. Wainwright | Buy |
| Dec-17-19 | Reiterated | H.C. Wainwright | Buy |
| Dec-16-19 | Reiterated | Guggenheim | Buy |
| Oct-16-19 | Initiated | Guggenheim | Buy |
| Sep-18-19 | Initiated | William Blair | Outperform |
| May-28-19 | Initiated | SunTrust | Buy |
| May-23-19 | Reiterated | H.C. Wainwright | Buy |
| Apr-08-19 | Initiated | SVB Leerink | Outperform |
| Mar-15-19 | Reiterated | H.C. Wainwright | Buy |
| Oct-03-16 | Resumed | Brean Capital | Buy |
| Dec-15-15 | Initiated | Cantor Fitzgerald | Buy |
| Dec-14-15 | Initiated | Ladenburg Thalmann | Buy |
View All
Axsome Therapeutics Inc Stock (AXSM) Latest News
Axsome Therapeutics' AXS-12 Data For Sleeping Disorder Boosts Confidence In Approval And Market Potential, Analyst Says - Benzinga
FY2024 Earnings Forecast for AXSM Issued By HC Wainwright - MarketBeat
Axsome's AXS-12 shows efficacy in narcolepsy trial By Investing.com - Investing.com Canada
Axsome reports positive Phase 3 data for AXS-12 for narcolepsy - MSN
Axsome Therapeutics eyes approval after Phase III narcolepsy win - Clinical Trials Arena
Positive Phase III data in narcolepsy from Axsome - The Pharma Letter
Axsome Therapeutics Announces AXS-12 Achieves Primary - GlobeNewswire
Axsome reports positive Phase 3 data for AXS-12 for narcolepsy (NASDAQ:AXSM) - Seeking Alpha
Axsome Therapeutics' (NASDAQ:AXSM) growing losses don't faze investors as the stock ascends 5.5% this past week - Yahoo Finance
Axsome's AXS-12 shows efficacy in narcolepsy trial - Investing.com India
Loomis Sayles & Co. L P Acquires 29,497 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome's AXS-12 Shows 77% Reduction in Narcolepsy Attacks in Phase 3 Trial Success | AXSM Stock News - StockTitan
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
Axsome Therapeutics (NASDAQ:AXSM) Receives "Buy" Rating from HC Wainwright - MarketBeat
Axsome shares reiterate Buy rating on strong Q3 results By Investing.com - Investing.com UK
Does Axsome Therapeutics (NASDAQ:AXSM) Have A Healthy Balance Sheet? - Simply Wall St
Eagle Asset Management Inc. Sells 15,854 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Landscape Capital Management L.L.C. Makes New $585,000 Investment in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
B. Metzler seel. Sohn & Co. Holding AG Invests $830,000 in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Migraine Market Forecasted to Surge in Coming Years, 2023-2032 Analysis by DelveInsight | Amgen, Teva Pharma, Eli Lilly, Teva Pharma, Axsome Therapeutics, AEON Biopharma, Charleston Laboratories - Barchart
Migraine Market Forecasted to Surge in Coming Years, 2023-2032 - openPR
Excessive Daytime Sleepiness Market to Witness Growth During the Forecast Period | Takeda, Theranexus, XW Pharma, Avadel, Axsome Therapeutics, Benevolent AI Bio - The Globe and Mail
(AXSM) Long Term Investment Analysis - Stock Traders Daily
Axsome Therapeutics' SWOT analysis: strong pipeline, sales growth boost stock outlook - Investing.com
StockNews.com Upgrades Axsome Therapeutics (NASDAQ:AXSM) to "Hold" - MarketBeat
Axsome's Q3 Earnings Beat, Auvelity Drives Sales Growth, Stock Up - MSN
Royce & Associates LP Has $2.02 Million Stock Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
First Turn Management LLC Sells 81,952 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Is It Too Late to Buy Viking Therapeutics Stock? - The Motley Fool
FY2024 EPS Estimates for AXSM Increased by Leerink Partnrs - MarketBeat
Axsome Therapeutics (AXSM) Q3 2024 Earnings Call Transcript - AOL
Axsome Therapeutics Inc (AXSM) Quarterly 10-Q Report - Quartzy
Axsome Advances Sleep Disorder Pipeline as Sunosi Prescriptions Increase in Q3 - Sleep Review
Equities Analysts Offer Predictions for AXSM FY2027 Earnings - MarketBeat
William Blair Issues Pessimistic Outlook for AXSM Earnings - MarketBeat
Axsome stock price target increased, rating held on strong sales - Investing.com
Axsome stock price target increased, rating held on strong sales By Investing.com - Investing.com UK
Axsome Therapeutics stock hits 52-week high at $98.61 By Investing.com - Investing.com Nigeria
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q3 2024 Earnings Call Transcript - Insider Monkey
Robert W. Baird Raises Axsome Therapeutics (NASDAQ:AXSM) Price Target to $116.00 - MarketBeat
Earnings call: Axsome Therapeutics reports record quarterly revenue By Investing.com - Investing.com Australia
Versor Investments LP Acquires New Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome Therapeutics’ Strong Q3 Growth Amidst Strategic Expansions - TipRanks
Axsome: Q3 Earnings Snapshot - Houston Chronicle
Earnings call: Axsome Therapeutics reports record quarterly revenue - Investing.com
Axsome Therapeutics stock hits 52-week high at $98.61 - Investing.com India
Axsome shares rise as Guggenheim lifts target to $135 By Investing.com - Investing.com UK
Axsome Therapeutics Q3 Earnings: Stay For Near Term Catalysts, Then Sell (AXSM) - Seeking Alpha
Axsome Therapeutics (NASDAQ:AXSM) Reaches New 52-Week HighShould You Buy? - MarketBeat
A Closer Look at 10 Analyst Recommendations For Axsome Therapeutics - Benzinga
Axsome Therapeutics Inc earnings beat by $0.04, revenue topped estimates - Investing.com
Axsome Therapeutics Inc Stock (AXSM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Axsome Therapeutics Inc Stock (AXSM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Saad Mark E | Director |
Sep 11 '24 |
Option Exercise |
3.67 |
11,016 |
40,429 |
21,018 |
| Saad Mark E | Director |
Sep 11 '24 |
Sale |
91.31 |
11,016 |
1,005,871 |
10,002 |
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):